Alphalyse A/S has pioneered the use of top-of-the-line mass spectrometry (LC-MS/MS) analysis since 2002. Our scientists have completed over 10,000 protein characterization analyses and more than 700 LC-MS-based residual host cell protein (HCP) projects under GMP and non-GMP. As a CRO, we offer HCP analysis services to support biopharmaceutical R&D and manufacturing of patient-safe products such as therapeutic proteins, vaccines, cell & gene therapies.
Monday, May 4, 18:00 - 18:15, room Sydney
AlphaMol Science Ltd. is a clinical-stage biotech focused on first-in-class GPCR-targeted small molecules. Its lead MRGPRX2 antagonist is advancing for mast cell–driven diseases, while a GPR75 program targets obesity with strong preclinical efficacy. Powered by a proprietary GPCR-AI platform, AlphaMol integrates computational biology and translational science to deliver innovative therapeutics.
Tuesday, May 5, 13:45 - 14:00, room Montreal
Arphamid Therapeutics is developing first-in-class RF-amide receptor antagonists targeting GPR103 and GPR10, two critical modulators of the brain's reward and hedonic systems. Our platform addresses high unmet medical needs in addiction, obesity, and anxiety/depression—markets with limited effective pharmacotherapies and significant global impact. In preclinical models, the RF-amide neuropeptide system orchestrates physiological functions linked to reward processing, food int
Tuesday, May 5, 13:45 - 15:00, room Singapore
- Athebio is a bootstrapped biotech founded in 2019, headquartered in Bio-Techpark Schlieren-Zürich
- Athebio developed an ultra-stable Athebody® DARPin to enable novel targeted biotherapeutic approaches
- Strategic partnerships for targeted radio-therapy (with Eli Lilly/Point) and targeted LNP (with Acuitas) established
- Seeking funding for Newco to develop game changing biotherapeutics for GI related diseases (IBD), by direct targeting of gut epithelium and tissue
Tuesday, May 5, 14:45 - 15:00, room Singapore
Azafaros is a clinical-stage company, led by a team of highly experienced industry experts, which aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. Azafaros is supported by a syndicate of leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Monday, May 4, 15:15 – 15:30, room Montreal
Basilea (SIX:BSLN) is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative treatments for severe bacterial and fungal infections. We successfully launched two hospital brands, the antifungal Cresemba and the antibiotic Zevtera. In addition, we have preclinical and clinical anti-infective assets in our portfolio.
Monday, May 4, 16:45 - 17:00, room Montreal
BioAgilytix and 360biolabs deliver a unified global bioanalytical strategy, combining the speed and clinical advantages of early-phase development in Australia with integrated PK, immunogenicity, biomarker, and CMC testing across Europe and the United States. Under harmonized quality systems and shared scientific leadership, we support programs from first-in-human through global late-phase studies.
Global Bioanalysis for Every Phase, Every Modality.
Tuesday, May 5, 14:15 - 14:30, room Sydney
Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. Biodelphis' APICore drug discovery platform enables the development of first- and best-in-class therapeutics targeting proteases. It combines the precision of targeted carriers with the potency and selectivity of peptide inhibitors to address the on-target and off-tissue toxicity limitations associated with conventional small-molecule inhibitors.
Tuesday, May 5, 15:30 - 15:45, room Singapore
CanVirex AG is a Swiss biotech company developing next‑generation cancer immuno‑virotherapies for solid tumors. As a spin‑off from Heidelberg University Hospital, CanVirex leverages a proven measles vaccine vector to deliver immunotherapeutics. The platform is supported by promising preclinical findings and early clinical experience from compassionate‑use settings, supporting further development.
Monday, May 4, 16:00 - 16:15, room Montreal
Carterra® is a leading provider of innovative technologies designed to accelerate therapeutic discovery. Since its 2018 launch, its Surface Plasmon Resonance (SPR) platforms are used by all top 20 pharma companies, major CROs, and leading biotechs worldwide. Its high-throughput SPR systems enable label-free screening and characterization of large and small molecules in one step, combining patented microfluidics with real-time HT-SPR and advanced analytics.
Tuesday, May 5, 15:45 - 16:00, room Sydney
Celonic is a “Pure Play” Mammalian Biologics CDMO. It's mission is to help its customers, primarily small to large Biotech companies, bring life-saving drugs to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial mid-size GMP manufacturing facilities in Heidelberg, Germany.
Monday, May 4, 14:30 - 14:45, room Montreal
Tuesday, May 5, 12:30 - 12:45, room Montreal
ClexBio has developed a proprietary biological platform that enables stem cell therapies to function safely in solid tissues. Our lead program, a liver implant for acute liver failure, has demonstrated strong preclinical function and durability. We are advancing toward IND-enabling studies and building strategic partnerships with biopharma to expand into additional indications such as type 1 diabetes and cardiac repair. We have a $10M round ongoing - term sheet secured.
Tuesday, May 5, 15:00 - 15:15, room Singapore
Cube Biotech specializes in solving complex problems in protein research, with a specific emphasis on the challenging class of membrane proteins. We take pride in covering all stages of protein preparation utilizing our NativeMP copolymer stabilization platform, protein purification capabilities, biophysical target characterization applications, and structure determination via cryo-EM or crystallography.
Monday, May 4, 16:00 - 16:15, room Sydney
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery. We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients.
Tuesday, May 5, 13:30 - 13:45, room Sydney
Diatheva develops therapeutic antibodies for oncology and infectious diseases. DIA12.3 is a fully human IgG1 mAb targeting the CEACAM1 immune checkpoint. Currently in preclinical development it is designed to overcome resistance to ICIs therapies in solid tumors including NSCLC, bladder and pancreatic cancers by restoring NK and T-cell cytotoxicity. Our pipeline includes additional mAbs for leukemia and resistant fungal infections. We seek strategic partners for Phase 1 entry
Tuesday, May 5, 14:15 - 14:30, room Montreal
Effective topical treatment of the esophagus is difficult due to the ultra-short transit time of only seconds from mouth to stomach. EsoCap has developed a versatile drug delivery platform that enables efficient, localized administration of small molecules, antibodies, and RNA-based therapies. The technology supports improved treatment of EoE, reflux disease, esophageal cancer, and other gastrointestinal disorders by enhancing mucosal contact and therapeutic precision.
Monday, May 4, 16:15 - 16:30, room Montreal
EvlaBio is developing a first-in-class therapy to address Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease (CKD), a critical unmet medical need affecting millions worldwide. CKD affects more than 10% of the global population. LVH prevalence increases with CKD progression, affecting approx. 30-45% of patients in early stages and up to 80% of patients on dialysis. Cardiovascular disease remains the leading cause of mortality in this population.
Monday, May 4, 15:30 - 15:45, room Singapore
Genevant Sciences is a leading nucleic acid delivery solutions company with best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology. Our selective collaboration business model enables us to partner with innovative payload companies in the gene editing, and RNA editing, therapeutic and vaccine spaces to bring emerging technologies into and through the clinic.
Monday, May 4, 15:30 - 15:45, room Montreal
Genomics is a science-led transatlantic TechBio combining large-scale genetic and health data with proprietary analytics to accelerate drug discovery and advance predictive, preventative healthcare. Our mission is to help people lead longer, healthier lives. Today, we are collaborating with some of the world’s leading healthcare organisations and helping them to predict, prevent, treat, and cure. Genomics is one of Britain’s fastest growing private tech companies.
Tuesday, May 5, 14:00 - 14:15, room Sydney
HDI Global offers a wide range of insurance solutions for startups, medium-sized businesses, large companies, and international corporate groups. As a partner in transformation, HDI combines local expertise with a global network, providing worldwide coverage and innovative solutions for new technologies and risks. For life sciences, HDI offers specialised cover - such as product liability, recall costs, R&D protection, clinical trials, logistics, and cyber insurance.
Tuesday, May 5, 13:00 - 13:15, room Sydney
Hemastatx aims to transform field of bleeding disorders. A 2025 BaseLaunch company, Hemastatx'sLead program HMX-001 focuses on advancing afirst-in-class ADAMTS13 antibody addressing severe bleeding in patients with von Willebrand Factor (VWF) disorders, both congential and acquired. HMX-001 is based on an elaborate ex vivo and in vivo PoC package and a robust IP portfolio. We seek financing to advance our program into IND/CTA-enabling studies.
Monday, May 4, 15:15 - 15:30, room Singapore
Humion is a Swiss biotech startup developing next-generation TCR-based T-cell therapies for solid tumors. We decode the immune responses of cancer super responders - patients with exceptional, durable tumor control. This allows us to identify validated, tumor-reactive TCRs and translate them into precise, patient-derived therapeutics. Our lead program, Humion-1, targets NSCLC. The platform expands across solid tumors, addressing major unmet needs in oncology.
Monday, May 4, 15:45 - 16:00, room Singapore
INITS is a service company with more than 12 years of experience, supporting biotech developing new therapeutic products.
INITS is developing INITS SMO (Shared Manufacturing Organization), a 3,200 m² GMP biomanufacturing facility that will enable companies to manufacture clinical batches using INITS' GMP infrastructure, equipment and expert support while retaining full ontrol of their processes and IP. Services include DS, DP, F&F, Packaging, Product release and Supply.
Monday, May 4, 17:45 - 18:00, room Sydney
Our mission is to unlock the potential of life science innovation no matter where it originates. Johnson & Johnson teams aim to solve the world’s toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere. We know that a great idea can come from anywhere and we are proud of our strong track record of cultivating innovation and pairing our deep internal know-how with some of the most promising external innovation worldwide.
Tuesday, May 5, 15:15 - 15:30, room Sydney
KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. KBI works closely to personalize and rapidly accelerate drug development programs.
Monday, May 4, 17:30 - 17:45, room Sydney
LIDE Biotech is a preclinical oncology CRO dedicated to advancing translational medical research. Our core offering are preclinical in-vitro and in-vivo assays for IND-enabling drug evaluation studies. We over 200 CDX and 2300 PDX models across 40+ cancer types, with many naturally drug-resistant. Our proprietary 7-day in-vivo assays MiniPDX and IOFIVE offer fast in-vivo validation. Founded in 2011, we operate world-class, AAALAC-accredited SPF animal centers and BSL-2 labs.
Tuesday, May 5, 16:00 - 16:15, room Sydney
Light Chain Bioscience is a clinical-stage biotechnology company advancing therapies based on its proprietary bispecific antibody platform (κλ body)
κλ bodies fully retain the native structure of human IgG leading to low immunogenicity and improved safety in the clinic.
We enable unique mechanisms of action such as safe and selective CD47 targeting and tumor selective CD28 agonism to harness the immune system to treat cancer and other serious indications.
Monday, May 4, 15:45 - 16:00, room Montreal
MTx develops therapeutic antibodies for viral infections and cancer. Its proprietary DROPZYLLA® technology enables comprehensive screening of human antibody repertoires in recombinant form. Lead asset potravitug targets BK virus in kidney transplant recipients; Phase II data support a Phase III start in 2026. DROPZYLLA® also underpins MTx’s recombinant polyclonal IgG technology and the discovery of tumor-reactive antibodies from tumor-infiltrating B cells.
Tuesday, May 5, 13:15 - 13:30, room Montreal
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. MP develops targeted radiopharmaceuticals (incl. MP0712, lead Radio-DARPin candidate for SCLC in Phase 1/2a) and next-generation immune cell engagers for cancer patients. Founded in 2004, MP has offices in Zurich, Switzerland and Concord, MA, USA.
Tuesday, May 5, 12:45 - 13:00, room Montreal
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Learn more at www.msdlicensing.com.
Tuesday, May 5, 15:00 - 15:15, room Sydney
Nanolynx is developing first-in-class conditionally active nanobody-drug conjugates (CA-NDCs) for hard-to-treat solid tumors. Our IntelliBody™ platform combines ML-driven nanobody engineering with pH-gated tumor-selective activation, addressing the two fundamental failures of conventional antibody-drug conjugates (ADCs): poor tissue penetration and dose-limiting toxicity.
Tuesday, May , 15:15 - 15:30, room Singapore
Novago Therapeutics, a Swiss biotech company, is advancing NG004, an antibody inhibiting Nogo-A, to promote nerve regeneration in acute spinal cord injury. Currently, NG004 is in Phase Ib trials across Europe (dosing completed, excellent profile so far). Clinical PoC trial preparation is well underway, with the anticipated first patient treated in summer 2026. NovaGo Therapeutics is raising funds for a Series B round (majority subscribed) to fund this clinical PoC.
Monday, May 4, 17:15 - 17:30, room Montreal
Oculis is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet needs. Oculis’ late-stage pipeline includes OCS-01, a topical eye drop for DME; Privosegtor, a neuroprotective candidate for optic neuritis and NAION; and Licaminlimab, a topical anti-TNFα for DED. Headquartered in Switzerland, Oculis is led by an experienced management team and is supported by leading healthcare investors.
Monday, May 4, 15:00 - 15:15, room Montreal
OM Pharma transforms immune health with bacterial lysates-innovative therapies that train and strengthen the body’s natural defenses. By prioritising prevention, the company helps reduce infections and protect vulnerable populations. Headquartered in Geneva, where its biotech site is also based, OM Pharma’s products are available in 100 countries and reach 16 million people globally through a trusted network of partners and affiliates.
Monday, May 4, 17:00 – 17:15, room Montreal
Oncodesign Services supports preclinical research in targeted radiotherapy, oncology, and inflammation and immune-mediated diseases. We integrate pharmacology, imaging, and biodistribution to generate clinically relevant data that helps move programs forward. As a rapidly growing modality in oncology, targeted radiotherapy enables precision delivery of radiotherapeutic payloads to cancer cells, improving targeting while reducing off-target effects and healthy tissue damage.
Monday, May 4, 15:45 - 16:00, room Sydney
Ophthanova Therapeutics, a Swiss biotech company, is pioneering neurovascular therapies for retinal diseases with a focus on diabetic retinopathy. Its lead candidate, an anti-NogoA antibody NG050, promotes revascularisation and reduces vascular leakage—key drivers of disease progression. With strong preclinical data Ophthanova is preparing for a Phase 1b trial in 2028. The company has commenced raising a Series A to fund pre-clinical development up to InD.
Monday, May 4, 14:45 - 15:00, room Singapore
Parexel is among the world’s largest CROs, providing full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, we collaborate with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials for patients.
Monday, May 4, 15:15 - 15:30, room Sydney
Peptone is a biotechnology company using AI and experimental physics to design small-molecule therapeutics against intrinsically disordered proteins (IDPs) — the 6,200 human proteins that AlphaFold 3 cannot model. Founded in 2018 and based in Bellinzona, Switzerland, Peptone's proprietary HDX-MS platform and GPU-accelerated AI engines unlock previously "undruggable" targets implicated in cancer, neurodegeneration, and beyond.
Tuesday, May 5, 13:15 - 13:30, room Singapore
Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats. We strive to impact patients’ lives by advancing innovative treatments for severe diseases.
Our companies are developing innovative therapeutics for severe diseases and conditions. We are backing great teams with development programs that make a true difference for patients.
Monday, May 4, 14:30 – 14:45, room Singapore
We develop biparatopic antibodies as best-in-class therapies in oncology and autoimmunity. In oncology, we develop biparatopic ADCs against targets challenging to address with classical ADCs; in autoimmunity, we drive effector-independent combinatorial immunomodulation with checkpoint agonism as a foundation. Versant and NEA are our co-lead investors, and we have an oncology-focused co-development partnership with Pierre Fabre. First IND targeted 2027.
Tuesday, May 5, 13:30 - 13:45, room Singapore
Ropes & Gray’s healthcare and life sciences group serves the legal and business needs of leading industry participants. Our internationally recognized team counsels pharma, biotech, medical device, digital health, and technology companies, as well as hospital systems, academic centers, service providers, and investors. With global resources, including EU and Asia regulatory specialists, we deliver innovative solutions to help clients achieve their goals.
Tuesday, May 5, 15:30 - 15:45, room Sydney
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical need. Santhera holds an exclusive worldwide license from ReveraGen to AGAMREE® (vamorolone), a dissociative steroid investigated in DMD as an alternative to corticosteroids. AGAMREE is approved for DMD in the U.S., EU, UK, China, Hong Kong, and Canada.
Monday, May 4, 17:00 - 17:15, room Sydney
Shape Biopharmaceuticals is advancing a first-in-class, ultra-low-dose, long-acting, multi-target antibody-inducing immunotherapy platform that programs the immune system to address key drivers of cardiometabolic disease. It enables durable, multi-pathway modulation of lipid biology, reducing residual cardiovascular risk beyond current therapies, with robust in vivo LDL-C and triglyceride lowering. The platform offers expansion potential across multi-target opportunities.
Tuesday, May 5, 14:15 - 14:30, room Singapore
Switchkine is a preclinical-stage company engineering cytokines&ligands in a proprietary Duokine format to enable a multi-target approach to chronic inflammation. The Duokine platform combines two modules - a receptor ligand and a monomeric IL-10, engineered to retain activity in acidic environments-a hallmark of chronic inflammation. By targeting both lymphoid and myeloid drivers of disease, Duokines aim to restore homeostasis beyond the limits of single-target therapies.
Monday, May 4, 15:00 - 15:15, room Singapore
Ultimate Medicine (UM) is a Swiss preclinical biotech focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias. The company is pioneering a class of small molecules targeting elevated levels of a novel toxic metabolite that disrupts critical neuronal functions and accelerates disease progression. The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis.
Monday, May 4, 16:00 - 16:15, room Singapore
Vetter is a global leading (CDMO), headquartered in Germany, with production facilities in Germany, Austria, and the US. The company has extensive experience supporting biotechnology and pharmaceutical customers of all sizes. It guides partners through key steps, decisions, and transitions across the development cycle, from preclinical stages to Phase 3. Vetter supports injectable product candidates across a broad range of therapeutic applications and substance classes.
Monday, May 4, 16:45 - 17:00, room Sydney
